Literature DB >> 11246661

Selective reduction and recovery of invariant Valpha24JalphaQ T cell receptor T cells in correlation with disease activity in patients with systemic lupus erythematosus.

Y Oishi1, T Sumida, A Sakamoto, Y Kita, K Kurasawa, Y Nawata, K Takabayashi, H Takahashi, S Yoshida, M Taniguchi, Y Saito, I Iwamoto.   

Abstract

OBJECTIVE: To study the regulatory role of CD4-CD8- double-negative (DN) invariant T cell receptor (TCR) Valpha24JalphaQ T cells, a human counterpart of murine NK 1 + T cells, in the autoimmune process of systemic lupus erythematosus (SLE).
METHODS: We carried out a 2 step frequency analysis of DN Valpha24JalphaQ T cells in patients with SLE before and after prednisolone therapy; the frequency of DN Valpha24+ T cells was determined by 3 color FACS analysis and subsequently the frequency of Valpha24JalphaQ rearrangement among DN Valpha24+ T cells was determined by sequencing.
RESULTS: DN Valpha24+ T cells were significantly increased in patients with active SLE compared to healthy subjects. In healthy subjects, invariant Valpha24JalphaQ TCR dominated in DN Valpha24+ T cells at a high frequency (93-100%). However, the invariant Valpha24JalphaQ TCR was not detected in DN Valpha24+ T cells from patients with active SLE, and instead 2 to 9 Jalpha genes other than the invariant JalphaQ were oligoclonally expanded in the patients. In inactive SLE induced by prednisolone therapy, the invariant Valpha24JalphaQ TCR could be detected in DN Valpha24+ T cells from all the patients and dominated in most of the patients. Further, oligoclonally expanded Valpha24+ clones other than the invariant JalphaQ gene in active disease states were significantly decreased by prednisolone therapy.
CONCLUSION: The selective reduction of DN invariant Valpha24JalphaQ T cells is related to the disease progression of SLE, while DN TCR Valpha24 T cells other than Valpha24JalphaQ T cells constitute autoaggressive T cells in SLE.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11246661

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  24 in total

1.  Brief treatment with iNKT cell ligand α-galactosylceramide confers a long-term protection against lupus.

Authors:  Jun-Qi Yang; Peter J Kim; Ram Raj Singh
Journal:  J Clin Immunol       Date:  2011-10-15       Impact factor: 8.317

Review 2.  SLE: translating lessons from model systems to human disease.

Authors:  Ram Raj Singh
Journal:  Trends Immunol       Date:  2005-09-09       Impact factor: 16.687

3.  Disparate effects of depletion of CD1d-reactive T cells during early versus late stages of disease in a genetically susceptible model of lupus.

Authors:  J Jacinto; P J Kim; R R Singh
Journal:  Lupus       Date:  2011-11-07       Impact factor: 2.911

Review 4.  The role of invariant natural killer T cells in lupus and atherogenesis.

Authors:  Amy S Major; Ram R Singh; Sebastian Joyce; Luc Van Kaer
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

5.  Invariant natural killer T cells and TGF-beta attenuate anti-GBM glomerulonephritis.

Authors:  Laurent Mesnard; Alexandre C Keller; Marie-Laure Michel; Sophie Vandermeersch; Cédric Rafat; Emmanuel Letavernier; Yves Tillet; Eric Rondeau; Maria C Leite-de-Moraes
Journal:  J Am Soc Nephrol       Date:  2009-05-21       Impact factor: 10.121

Review 6.  Glycolipid targets of CD1-mediated T-cell responses.

Authors:  D B Moody; G S Besra
Journal:  Immunology       Date:  2001-11       Impact factor: 7.397

7.  The natural killer T cell ligand alpha-galactosylceramide prevents or promotes pristane-induced lupus in mice.

Authors:  Avneesh K Singh; Jun-Qi Yang; Vrajesh V Parekh; Jie Wei; Chyung-Ru Wang; Sebastian Joyce; Ram R Singh; Luc Van Kaer
Journal:  Eur J Immunol       Date:  2005-04       Impact factor: 5.532

8.  Testing the NKT cell hypothesis of human IDDM pathogenesis.

Authors:  Peter T Lee; Amy Putnam; Kamel Benlagha; Luc Teyton; Peter A Gottlieb; Albert Bendelac
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

9.  Skewed distribution of circulating activated natural killer T (NKT) cells in patients with common variable immunodeficiency disorders (CVID).

Authors:  Karina I Carvalho; Karina M Melo; Fernanda R Bruno; Jennifer E Snyder-Cappione; Douglas F Nixon; Beatriz T Costa-Carvalho; Esper G Kallas
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

10.  Intrinsic hyporesponsiveness of invariant natural killer T cells precedes the onset of lupus.

Authors:  J-Q Yang; P J Kim; R C Halder; R R Singh
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.